Peter J. Rosen

Medicine · Health Sciences

33h-index4.2kcitations127works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(24), Chronic Lymphocytic Leukemia Research(23), Multiple Myeloma Research and Treatments(21), Cancer Treatment and Pharmacology(14), Protein Degradation and Inhibitors(14)

Publications127 total

Data from A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
2023Open Access
Supplementary Table 1 from A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
2023Open Access
Supplementary Table 1 from A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
2023Open Access
Data from A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
2023Open Access
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma
Clinical Cancer Research·2018· 36 citedOpen Access
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma
British Journal of Haematology·2017· 12 cited
a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood·2015· 5 cited
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
Oncotarget·2015· 29 citedOpen Access
Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2015· 2 cited
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
Journal of Clinical Oncology·2014· 186 citedOpen Access
A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
Blood·2014
Antisepsis und antimikrobielle Vorgehensweise bei Katarakteingriffen: Ergebnisse einer europaweiten Erhebung
Klinische Monatsblätter für Augenheilkunde·2014
Examining the relationships between self‐efficacy, task‐relevant attentional control , and task performance: Evidence from event‐related brain potentials
British Journal of Psychology·2014· 59 cited
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)
Cancer Chemotherapy and Pharmacology·2014· 65 citedOpen Access
A phase 1/2 study of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology·2014· 1 cited
Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.
Journal of Clinical Oncology·2014· 9 cited
Disseminated Intravascular Coagulation Secondary to Advanced Pancreatic Cancer Treated Successfully with Combination Chemotherapy
Oncology·2014· 4 cited
The effects of social exclusion on the <scp>ERN</scp> and the cognitive control of action monitoring
Psychophysiology·2013· 35 citedOpen Access
Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer
Journal of Thoracic Oncology·2013· 36 citedOpen Access
An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
Cancer·2013· 106 cited
page 1 of 7Next →

Frequent Co-authors

Peter P. Lee(7), Lori Kunkel(4), Srđan Verstovšek(4), Francesco Passamonti(4), Alessandro Rambaldi(4), Giovanni Barosi(4), Elisa Rumi(4), Elisabetta Gattoni(4), Nancy Contel(4), Mario Cazzola(4), Hagop M. Kantarjian(4), Tiziano Barbui(4), Alessandro M. Vannucchi(4), Jason R. Themanson(4), Jeffrey Matous(3), Lisa Pieri(3), Ronald Paquette(3), Darrin M. Beaupre(3), Daniel D. Von Hoff(2), Mitesh J. Borad(2)